68-4

77/136

1) Johnson DB, Chandra S, Sosman JA: Immune Check-point Inhibitor Toxicity in 2018. JAMA, 2018; 320: 1702-1703. 2) Cortellini A, Friedlaender A, Banna GL, et al: Immune- related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes. Clin Lung Cancer, 2020; 21: 498-508. 3) Gonzalez RS, Salaria SN, Bohannon CD, Huber AR, Feely MM, Shi C. PD-1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory The authors received no financial support for the research.Author contributionsAH, HI, ST, and TY performed the histological evaluation; TO, SS performed data analysis and interpretation; AH, ST wrote the manuscript; and all authors approved the final manuscript.Conflicts of interest statementThe authors declare that they have no conflicts of interest.gastroenterocolitis’. Histopathology, 2017; 70: 558-567. 4) Yamauchi R, Araki T, Mitsuyama K, et al: The charac-teristics of nivolumab-induced colitis: an evaluation of three cases and a literature review. BMC Gastroenter-ology, 2018; 18: 135. 5) Chen JH, Pezhouh MK, Lauwers GY, Masia R: Histo-pathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies. Am J Surg Pathol, 2017; 41: 643-654. 6) Zhang ML, Neyaz A, Patil D, Chen J, Dougan M, Desh-pande V: Immune-Related Adverse Events in the Gastrointestinal Tract: Diagnostic Utility of Upper Gastrointestinal Biopsies. Histopathology, 2020; 76: 233-243. 7) Bavi P, Butler M, Serra S, Chetty R: Immune modula-tor-induced changes in the gastrointestinal tract. Histopathology, 2017; 71: 494-496. 8) Robilotti EV, Babady NE, Mead PA, et al: Determi-nants of COVID-19 disease severity in patients with cancer. Nat Med, 2020; 26: 1218-1223. 9) Garassino MC, Whisenant JG, Huang LC, et al: COVID- 19 in patients with thoracic malignancies (TERA-VOLT): first results of an international, registry-based, cohort study. Lancet Oncol, 2020; 21: 914-922.10) Luo J, Rizvi H, Preeshagul IR, et al: COVID-19 in patients with lung cancer. Ann Oncol, 2020; 31: 1386-1396.11) Castillo MD, Romero FA, Argüello E, Kyi C, Postow MA, Redelman-Sidi G: The Spectrum of Serious Infec-tions Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma. Clin Infect Dis, 2016; 63: 1490–1493. 397FundingReferences